GX-03 Hits 59.3% Clear/Almost Clear at Week 4 in Phase 2a
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Interim Phase 2a data for GX-03 in atopic dermatitis show 59.3% of patients reaching clear or almost clear skin by week 4 versus 30.4% on vehicle, and 40.7% achieving EASI-100 at week 8 versus 17.4%. The numbers are directionally strong, but the release gives no statistical significance and the dataset is small at n=50. This builds on the interim efficacy signal disclosed in the August 8-K and the stronger presentation update in October, now with actual response rates attached. The company is adaptively refining the Phase 2b design using the first 50 completers, so the next real read is later-stage data. A hidradenitis suppurativa Phase 2a is targeted to enroll its first patient in Q1 2027, a target rather than a confirmed date. With a $5.85M quarterly net loss and going-concern language in the last 10-Q, positive clinical news matters for financing leverage as much as for the program itself.
At the time of this announcement, TTRX was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $299.2M. The 52-week trading range was $2.57 to $16.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.